AI Article Synopsis
- * A case study of an ovarian cancer patient shows that rhabdomyolysis recurred after changing the chemotherapy regimen, suggesting a link with specific drugs like gemcitabine and paclitaxel rather than patient-specific factors.
- * If rhabdomyolysis is resolved, chemotherapy can be resumed based on the patient's overall health, but it's crucial to choose alternative drugs carefully to prevent recurrence and monitor the patient's condition closely.
Article Abstract
Introduction: The incidence of chemotherapy-induced rhabdomyolysis is rare, but it is a syndrome that may cause death and should be paid attention to clinically.
Case Presentation: Here, we report a case of rhabdomyolysis in an ovarian cancer patient after chemotherapy. After the symptoms were relieved, the chemotherapy regimen was changed, and rhabdomyolysis occurred again.
Conclusion: The occurrence of rhabdomyolysis is mainly caused by certain specific chemotherapy drugs such as gemcitabine and paclitaxel and is not closely related to other factors such as the patient's constitution or genetic factors. And the occurrence of rhabdomyolysis can be caused by conventional doses of drugs rather than high dose. If rhabdomyolysis occurs and is completely relieved, chemotherapy may be considered again depending on the patient's condition and physical condition. However, caution should be exercised in selecting drugs to avoid recurrence of rhabdomyolysis, and the condition should be closely monitored.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575922 | PMC |
| http://dx.doi.org/10.1159/000542103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!